MedDataX Logo

Turkish of the SARS-CoV-2 Anxiety Scale

NCT ID: NCT04490473

Last Updated: 2020-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-24

Study Completion Date

2021-04-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The coronavirus outbreak has adversely affected individuals in the community, as in the rest of the world. However, in order to carry out this epidemic period in a healthy and conscious manner, determining the anxiety levels of individuals in the society and supporting them psychologically is of great importance. In order to achieve this, healthcare professionals working clinically or academically have important duties. This study was planned to test its validity and reliability in order to adapt the Coronavirus Anxiety Scale to Turkish.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Coronaviruses can be seen in animals and humans as infections that can be mild and severe in society. The SARS-CoV-2 virus, a type of coronavirus, started in China in December 2019 and has spread worldwide as of January 2020. The absence of vaccine and treatment for SARS-CoV-2 disease threatens health worldwide and significantly affects people's daily routine. In China, where the pandemic started, shopping malls and schools were closed for a while, and city entrances and exits were stopped for a while. Although there are similar practices in excellence, as in many countries, measures such as curfew, nursery and school closure continue to be taken for under-20s and over-65s. . The coronavirus epidemic that affects our entire life is not fully known about the disease process, WHO is defined as the pandemic of the epidemic, the nearest contact is the greatest risk of transmission, and the loss of many lives during this process affects all individuals in the society negatively and increases the level of anxiety .

It is a psychological reaction involving many emotions such as anxiety, stress, or anxiety, fear and distress that arise in a situation that threatens the safety of the individual. Conditions such as uncertainty, various diseases (cancer, epidemic, etc.) and losing a relative can cause anxiety. Outbreaks that occur suddenly and are at risk of death are among these reasons.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anxiety SARS-CoV Infection

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Coronavirus Anxiety Scale COVID-19 Anxiety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This research will be conducted in a methodological manner in order to conduct the validity and reliability studies of the Coronary Virus Anxiety Scale in Turkish.
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

volunteer group

Only volunteer participants will be included in the research. Survey forms will be sent to individuals online. Individuals who agree to participate in the study will fill in the questionnaire and send it back online.

Group Type OTHER

survey work

Intervention Type OTHER

Survey forms will be sent to individuals online. Information about the study will be given to individuals with the informative text at the beginning of the questionnaire form. Individuals who agree to participate in the study will fill in the questionnaire and send it back online.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

survey work

Survey forms will be sent to individuals online. Information about the study will be given to individuals with the informative text at the beginning of the questionnaire form. Individuals who agree to participate in the study will fill in the questionnaire and send it back online.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* individuals agree to participate in the study
* 18 years old,
* Lack of visual obstacle,
* Knowing how to speak, read and write in Turkish.

Exclusion Criteria

* individuals refuse to participate in the study
* 18 years old,
* Visually impaired,
* Does not know how to speak, read and write in Turkish
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

DILEK SAYIK

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

DILEK SAYIK

Principal Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

DILEK SAYIK

Role: PRINCIPAL_INVESTIGATOR

ESKISEHIR OSMANGAZI UNIVERSTY

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Eskisehir Osmangazi University

Eskişehir, , Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

DILEK SAYIK

Role: CONTACT

Phone: 5065416642

Email: [email protected]

DENIZ YIGIT

Role: CONTACT

Phone: 05428092848

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

AYFER AÇIKGÖZ

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Benli, S. S., & Yıldırım, A. (2017). Hemşirelerde yaşam doyumu ve ölüme karşı tutum arasındaki ilişki. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi, 6(4), 167-179

Reference Type BACKGROUND

Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988 Dec;56(6):893-7. doi: 10.1037//0022-006x.56.6.893. No abstract available.

Reference Type BACKGROUND
PMID: 3204199 (View on PubMed)

Chen P, Mao L, Nassis GP, Harmer P, Ainsworth BE, Li F. Coronavirus disease (COVID-19): The need to maintain regular physical activity while taking precautions. J Sport Health Sci. 2020 Mar;9(2):103-104. doi: 10.1016/j.jshs.2020.02.001. Epub 2020 Feb 4. No abstract available.

Reference Type BACKGROUND
PMID: 32099716 (View on PubMed)

Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020 Apr;92(4):418-423. doi: 10.1002/jmv.25681. Epub 2020 Feb 7.

Reference Type BACKGROUND
PMID: 31967327 (View on PubMed)

Faraji A, Karimi M, Azizi SM, Janatolmakan M, Khatony A. Occupational stress and its related demographic factors among Iranian CCU nurses: a cross-sectional study. BMC Res Notes. 2019 Sep 27;12(1):634. doi: 10.1186/s13104-019-4674-5.

Reference Type BACKGROUND
PMID: 31558161 (View on PubMed)

Lee SA. Coronavirus Anxiety Scale: A brief mental health screener for COVID-19 related anxiety. Death Stud. 2020;44(7):393-401. doi: 10.1080/07481187.2020.1748481. Epub 2020 Apr 16.

Reference Type BACKGROUND
PMID: 32299304 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Ayfer AÇIKGÖZ

Identifier Type: OTHER

Identifier Source: secondary_id

ERTUĞRUL ÇOLAK

Identifier Type: OTHER

Identifier Source: secondary_id

DENİZ YİĞİT

Identifier Type: OTHER

Identifier Source: secondary_id

ÖZLEM MUMCU

Identifier Type: OTHER

Identifier Source: secondary_id

DSAYIK2

Identifier Type: -

Identifier Source: org_study_id